Increased AbbVie Offer Could Mark The Beginning Of The End Of Shire Saga
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if Shire’s board rejects AbbVie’s July 8 offer, about 11% higher in total value than its previous bid, Wall Street thinks this will serve as a precursor to buyout negotiations between the two companies. The latest offer would leave Shire shareholders with 24% equity in the resulting new company.